NASDAQ:DYAI Dyadic International (DYAI) Stock Forecast, Price & News $2.28 +0.05 (+2.24%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$2.19▼$2.3050-Day Range$1.34▼$2.2852-Week Range$1.12▼$3.56Volume31,698 shsAverage Volume33,354 shsMarket Capitalization$65.69 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Dyadic International MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside163.2% Upside$6.00 Price TargetShort InterestHealthy2.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.14) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector520th out of 1,006 stocksBiological Products, Except Diagnostic Industry80th out of 167 stocks 3.3 Analyst's Opinion Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Dyadic International has a forecasted upside of 163.2% from its current price of $2.28.Amount of Analyst CoverageDyadic International has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.21% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Dyadic International has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYAI. Previous Next 3.9 News and Social Media Coverage News SentimentDyadic International has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Dyadic International this week, compared to 1 article on an average week.Search Interest1 people have searched for DYAI on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Dyadic International to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by Insiders27.00% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.09% of the stock of Dyadic International is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyadic International are expected to grow in the coming year, from ($0.14) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dyadic International (NASDAQ:DYAI) StockDyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.Read More Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address DYAI Stock News HeadlinesMay 26, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Dyadic International, Inc. Issued By HC Wainwright (NASDAQ:DYAI)May 24, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Dyadic International (DYAI)June 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 17, 2023 | americanbankingnews.comDyadic International, Inc. (NASDAQ:DYAI) Sees Large Growth in Short InterestMay 16, 2023 | americanbankingnews.comFY2023 EPS Estimates for Dyadic International, Inc. Boosted by Analyst (NASDAQ:DYAI)May 14, 2023 | americanbankingnews.comContrasting Zura Bio (NASDAQ:ZURA) and Dyadic International (NASDAQ:DYAI)May 12, 2023 | finance.yahoo.comDyadic International (NASDAQ:DYAI) shareholders are up 12% this past week, but still in the red over the last three yearsMay 11, 2023 | finance.yahoo.comDYAI: Abundant Opportunities in Products and Animal & Human HealthJune 1, 2023 | Legacy Research (Affiliate) (Ad)“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.May 10, 2023 | finance.yahoo.comDyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressMay 10, 2023 | finance.yahoo.comDyadic to Participate at Two Industry Events in MayMay 9, 2023 | marketwatch.comDyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus(TM)May 8, 2023 | finance.yahoo.comDyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™April 26, 2023 | finance.yahoo.comDyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023April 18, 2023 | finance.yahoo.comDyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production PlatformApril 12, 2023 | finance.yahoo.comDyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African ContinentApril 5, 2023 | americanbankingnews.comDyadic International, Inc. (NASDAQ:DYAI) Sees Significant Increase in Short InterestApril 1, 2023 | finance.yahoo.comDyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call TranscriptApril 1, 2023 | finance.yahoo.comDyadic International Full Year 2022 Earnings: Revenues DisappointMarch 30, 2023 | finance.yahoo.comDYAI: 2022 ResultsMarch 30, 2023 | finance.yahoo.comDyadic to Present at World Vaccine Congress Washington 2023March 29, 2023 | finance.yahoo.comDyadic Reports 2022 Year End Results and Recent Company ProgressMarch 28, 2023 | americanbankingnews.comDyadic International (DYAI) Scheduled to Post Quarterly Earnings on WednesdayMarch 15, 2023 | finance.yahoo.comDyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023March 7, 2023 | finance.yahoo.comDyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine CandidateMarch 1, 2023 | finance.yahoo.comDyadic to Present at Roth Investor Conference and Upcoming Industry EventsFebruary 2, 2023 | finance.yahoo.comDyadic to Participate in Two Upcoming Investor ConferencesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address DYAI Company Calendar Last Earnings3/29/2023Today5/31/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DYAI CUSIPN/A CIK1213809 Webwww.dyadic.com Phone(561) 743-8333Fax561-743-8343Employees7Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+163.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,730,000.00 Net Margins-251.43% Pretax Margin-251.43% Return on Equity-68.23% Return on Assets-55.62% Debt Debt-to-Equity RatioN/A Current Ratio6.83 Quick Ratio6.83 Sales & Book Value Annual Sales$2.93 million Price / Sales22.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.37 per share Price / Book6.16Miscellaneous Outstanding Shares28,810,000Free Float21,032,000Market Cap$65.69 million OptionableNot Optionable Beta0.69 Key ExecutivesMark A. EmalfarbPresident, Chief Executive Officer & DirectorPing W. RawsonChief Financial OfficerRonen TcheletVice President-Research & Business DevelopmentJoseph P. HazeltonChief Business OfficerKey CompetitorsMiNK TherapeuticsNASDAQ:INKTBlack Diamond TherapeuticsNASDAQ:BDTXTradeUP AcquisitionNASDAQ:UPTDTCR2 TherapeuticsNASDAQ:TCRRCognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsidersRonen TcheletSold 1,089 sharesTotal: $3,713.49 ($3.41/share)View All Insider Transactions DYAI Stock - Frequently Asked Questions Should I buy or sell Dyadic International stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DYAI shares. View DYAI analyst ratings or view top-rated stocks. What is Dyadic International's stock price forecast for 2023? 2 brokerages have issued 1 year target prices for Dyadic International's stock. Their DYAI share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price. View analysts price targets for DYAI or view top-rated stocks among Wall Street analysts. How have DYAI shares performed in 2023? Dyadic International's stock was trading at $1.23 at the beginning of the year. Since then, DYAI stock has increased by 85.4% and is now trading at $2.28. View the best growth stocks for 2023 here. Are investors shorting Dyadic International? Dyadic International saw a decrease in short interest in May. As of May 15th, there was short interest totaling 448,500 shares, a decrease of 5.3% from the April 30th total of 473,600 shares. Based on an average daily trading volume, of 39,000 shares, the short-interest ratio is currently 11.5 days. Approximately 2.2% of the company's shares are sold short. View Dyadic International's Short Interest. When is Dyadic International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our DYAI earnings forecast. How were Dyadic International's earnings last quarter? Dyadic International, Inc. (NASDAQ:DYAI) released its earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The biotechnology company earned $0.74 million during the quarter, compared to the consensus estimate of $1.45 million. Dyadic International had a negative trailing twelve-month return on equity of 68.23% and a negative net margin of 251.43%. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Ampio Pharmaceuticals (AMPE), Alibaba Group (BABA) and Chimerix (CMRX). What is Dyadic International's stock symbol? Dyadic International trades on the NASDAQ under the ticker symbol "DYAI." How do I buy shares of Dyadic International? Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dyadic International's stock price today? One share of DYAI stock can currently be purchased for approximately $2.28. How much money does Dyadic International make? Dyadic International (NASDAQ:DYAI) has a market capitalization of $65.69 million and generates $2.93 million in revenue each year. The biotechnology company earns $-9,730,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. How can I contact Dyadic International? Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The official website for the company is www.dyadic.com. The biotechnology company can be reached via phone at (561) 743-8333, via email at prawson@dyadic.com, or via fax at 561-743-8343. This page (NASDAQ:DYAI) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.